Predicting Mortality in Systemic Sclerosis

SCUSSEL-LONZETTI, LILIAN; Joyal, F; Raynauld, Jean‐Pierre; Roussin, André; Rich, Éric; Goulet, Jean; Raymond, Yves; Senécal, Jean‐Luc

doi:10.1097/00005792-200203000-00005

Cited by 306 publications

(76 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, SSc-IP is observed more frequently in women and typically occurs in the third to fi fth decades of life, whereas idiopathic pulmonary fi brosis is more common in men, with a typical age of onset after the fi fth decade. 3,[23][24][25][26] Thus, when considering the genetic factors that increase the risk of developing SSc-IP, it is not surprising that SSc-IP appears to be distinct from the idiopathic forms of IP. In fact, based on our fi ndings, we would predict that the immu nologic causes of IP do not involve the MUC5B promoter polymorphism.…”

Section: Resultsmentioning

confidence: 99%

The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis

Peljto

Steele

Fingerlin

et al. 2012

Chest

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis

Peljto

Steele

Fingerlin

et al. 2012

Chest

View full text Add to dashboard Cite

“…SSc is a collagen tissue disorder in which pulmonary involvement is very frequent and is associated with poor prognosis [57][58][59]. The most common pulmonary complications are fibrosing alveolitis of systemic sclerosis (FASSc), and pulmonary vascular disease, which is the leading cause of death in SSc [60], surpassing renal involvement.…”

Section: Systemic Sclerosis (Scleroderma)mentioning

confidence: 99%

“…The most common pulmonary complications are fibrosing alveolitis of systemic sclerosis (FASSc), and pulmonary vascular disease, which is the leading cause of death in SSc [60], surpassing renal involvement. In SSc, 25% of all patients will develop clinically significant ILD and severe restrictive lung disease has been reported in 13% [57][58][59]. Therefore, the identification and staging of pulmonary involvement is very important for the management of the disease.…”

Section: Systemic Sclerosis (Scleroderma)mentioning

confidence: 99%

Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement: Table 1—

Antoniou¹,

Margaritopoulos²,

Economidou³

et al. 2009

Eur Respir J

151

122

View full text Add to dashboard Cite

The connective tissue disorders (CTDs), also called collagen vascular diseases (CVDs), represent a heterogeneous group of immunologically mediated inflammatory disorders with a large variety of affected organs. Individuals with a CTD (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, polymyositis/dermatomyositis and mixed connective tissue disease) are susceptible to respiratory involvement. When the lungs are affected, an increasing mortality and morbidity in CVDs occurs. Interstitial lung disease (ILD) is established as a clinical corollary across the spectrum of CTDs, with an overall incidence estimated at 15%.Therefore, pivotal clinical dilemmas remain in the evaluation and management of ILD involvement in CVDs. Critical questions are the presence of fibrosis and whether the disease is clinically significant. Moreover, the clinician has to decide if treatment is warranted and which is the best therapeutic approach. The use of additional tests, such as pulmonary function tests, high-resolution computed tomography scan, bronchoalveolar lavage fluid and surgical lung biopsy, deserves better discussion. The present review focuses on establishing the diagnosis of ILD in CTD, and on evaluating disease activity and prognosis. This will provide the basis for therapeutic decisions that will be discussed, including an overview of recent advances.

show abstract

“…Установлена более высокая конкордантность уровней антинуклеарных антител у монозиготных близнецов с ССД по сравнению с дизиготными [13]. Выявлена высокая час-тота ССД в некоторых генетически изолированных попу-ляциях, таких как индейцы племени Choktaw [14].…”

Section: результатыunclassified

Fas Apoptotic Gene Polymorphism (-670a/G) Is Associated With Clinical Phenotypes of Systemic Sclerosis in a Russian Population: A Pilot Study

Крылов¹,

Ананьева²,

Koneva³

et al. 2017

rsp

View full text Add to dashboard Cite

Predicting Mortality in Systemic Sclerosis

Cited by 306 publications

References 38 publications

The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis

The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis

Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement: Table 1—

Fas Apoptotic Gene Polymorphism (-670a/G) Is Associated With Clinical Phenotypes of Systemic Sclerosis in a Russian Population: A Pilot Study

Contact Info

Product

Resources

About